Woodruff Emlen

Dr. Woody Emlen is a graduate of Stanford University and the University of California (San Diego) School of Medicine.

Dr. Emlen was a professor of medicine and immunology at the University of Washington and University of Colorado Health Sciences Center for almost 20 years, where his practice was in internal medicine and rheumatology (arthritis) and his research focused on inflammatory and autoimmune diseases. In the late 1990s, Dr. Emlen left academic medicine to pursue a career in biotechnology, serving as vice president of scientific affairs for Palo Alto-based InterMune Pharmaceuticals. In 2004, he co-founded his own Denver-based biotechnology company, Taligen Therapeutics, serving as a chief operating officer until the company’s acquisition by Alexxion in 2011. Dr. Emlen is currently retired from medicine but serves on the boards of several early-stage biotechnology companies.